Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced the absorption merger of its affiliate Huanggang Yong'an Daily Chemical Co., Ltd. by its wholly-owned subsidiary Hubei Tian'an Daily Chemical Co., Ltd. This merger aims to integrate resources, improve efficiency, and reduce costs [1] Group 1: Merger Details - The merger will not involve any cash payments, and shareholders of Huanggang Daily Chemical will exchange their shares for direct equity in Tian'an Daily Chemical [1] - After the merger, Huanggang Daily Chemical will be dissolved, and all its assets, liabilities, and equity will be legally inherited by Tian'an Daily Chemical [1] - The company's previous investment of 30 million yuan in Huanggang Daily Chemical will convert into a direct investment in Tian'an Daily Chemical, maintaining a shareholding ratio of 6.5217% [1] Group 2: Strategic Implications - The merger is expected to optimize the management structure of the affiliate, reduce management costs, and enhance decision-making efficiency [1] - This move aligns with the overall development strategy of the company, aiming to fully leverage the economic benefits of asset integration [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced a merger where its subsidiary Huanggang Yong'an Daily Chemical Co., Ltd. will be absorbed by its wholly-owned subsidiary Hubei Tianan Daily Chemical Co., Ltd. This merger aims to optimize management structure, reduce costs, and enhance decision-making efficiency, aligning with the company's overall development strategy [1]. Summary by Relevant Sections - **Merger Details** - Huanggang Yong'an Daily Chemical will be merged into Hubei Tianan Daily Chemical, with Tianan Daily Chemical as the surviving entity and Huanggang Daily Chemical being dissolved [1]. - The merger will not involve cash payments; shareholders of Huanggang Daily Chemical will exchange their shares for direct equity in Tianan Daily Chemical [1]. - After the merger, the company's investment of 30 million yuan in Huanggang Daily Chemical will convert to a direct investment in Tianan Daily Chemical, maintaining a shareholding ratio of 6.5217% [1]. - **Strategic Benefits** - The merger is expected to optimize the management structure of the subsidiary, reduce management costs, and improve decision-making efficiency [1]. - The consolidation is anticipated to leverage economic benefits from asset integration, which is in line with the company's strategic development goals [1].

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) is consolidating resources and improving efficiency by merging its subsidiary Huanggang Yong'an Daily Chemical Co., Ltd. into its wholly-owned subsidiary Hubei Tian'an Daily Chemical Co., Ltd. [1] Group 1 - The merger will not involve any cash payments, and shareholders of Huanggang Daily Chemical will exchange their equity for direct ownership in Tian'an Daily Chemical through a share swap [1] - After the merger, Huanggang Daily Chemical will be dissolved, and all its assets, liabilities, and equity will be legally inherited by Tian'an Daily Chemical [1] - The company's previous investment of 30 million yuan in Huanggang Daily Chemical will convert into a direct investment in Tian'an Daily Chemical, maintaining a shareholding ratio of 6.5217% [1]

Group 1 - The core viewpoint of the news is that Yong'an Pharmaceutical has shown significant stock performance, with a year-to-date increase of 125.80% and a recent price of 17.82 CNY per share, reflecting strong market interest and trading activity [1][2] - As of October 31, the number of shareholders for Yong'an Pharmaceutical is 57,100, a decrease of 4.28% from the previous period, while the average circulating shares per person increased by 4.48% to 4,296 shares [2] - The company operates primarily in the pharmaceutical sector, focusing on the research, production, and sales of taurine products, which account for 64.14% of its main business revenue [1][2] Group 2 - For the period from January to September 2025, Yong'an Pharmaceutical reported a revenue of 577 million CNY, a year-on-year decrease of 6.72%, and a net profit attributable to the parent company of 25.5 million CNY, down 58.78% year-on-year [2] - The company has distributed a total of 401 million CNY in dividends since its A-share listing, with 87.7 million CNY distributed over the past three years [3]

Group 1 - Semiconductor Manufacturing International Corporation (SMIC) plans to acquire 47% equity in SMIC North, with due diligence and evaluation processes still ongoing [1][2] - Zhuhai Gree Supply Chain intends to convert a debt of 200 million yuan into equity to increase capital for Shenzhen Haoneng Technology, changing its status from a wholly-owned subsidiary to a controlling subsidiary [3] - China Huadian Corporation is set to invest 12.043 billion yuan in a combined heat and power generation project integrated with renewable energy in Heilongjiang [4] Group 2 - Yong'an Pharmaceutical announces that some directors and senior management plan to reduce their holdings by up to 0.0799% of the total shares [5] - Lihua Co. reports a 11.44% year-on-year increase in chicken sales revenue for October, totaling 1.461 billion yuan [6] - Degu Technology intends to terminate the acquisition of 100% equity in Haowei Technology due to difficulties in meeting the demands of all parties involved [7] Group 3 - Guocheng Mining plans to pay 3.168 billion yuan in cash to acquire 60% equity in Guocheng Industrial [8] - Yingtang Intelligent Control intends to acquire 100% equity in Guanglong Integration and 80% equity in Aojian Microelectronics, with stock resuming trading on November 10 [9] - Shanshan Holdings announces that its actual controller and major shareholder have divorced, resulting in a change in control [10] Group 4 - Nutaige plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on robotics and related components [11] - Chengxing Co. reports that its Jiangyin factory is currently under temporary shutdown for rectification due to a raw material leak [12] - Xindong Holdings announces that its shareholder Hainan Zhuhua plans to reduce its stake by up to 3% [13] Group 5 - Yonghui Supermarket's vice president has completed a share reduction of 0.0012% [14] - Xi'an Tourism plans to issue A-shares to raise no more than 300 million yuan for working capital and bank loan repayment [15] - Xiaogoods City has successfully acquired land use rights for a commercial site in Yiwu for 3.223 billion yuan [16][17] Group 6 - Tongda Chuangzhi announces a cash dividend of 6 yuan per 10 shares for the 2025 interim period [18] - Shen Nan Electric A received a government subsidy of 8.0518 million yuan, accounting for 36.75% of its last fiscal year's net profit [19] - Founder Technology's subsidiary plans to invest 1.364 billion yuan in an AI expansion project in Chongqing [20] Group 7 - Hezhong China reports significant stock trading fluctuations, indicating a "hot potato" effect [21] - Hengrui Medicine's subsidiary has received approval for clinical trials of SHR-4610 injection for late-stage solid tumors [22] - Sihua Holdings announces the termination of a restructuring investment agreement and continues to seek potential investors [23] Group 8 - Yingwei Technology's subsidiary has won a 27.78% share of a project from China Mobile [24] - Dabeinong reports a 45.20% year-on-year increase in pig sales for October, totaling 5.79 billion yuan [25] - Meihua Biotech's major shareholder has been sentenced for market manipulation, but it does not affect the company's operations [26] Group 9 - Zhongyi Da plans to terminate the issuance of A-shares to specific investors [27] - Zhongji Oil and Gas has received a notice of investigation from the China Securities Regulatory Commission regarding trading violations [28] - China International Trade Corporation announces the resignation of its chairman due to work reasons [29] Group 10 - GAC Group reports a decline in October vehicle sales by 8.10% [30] - Dameng Data has invested 100 million yuan to establish an investment fund focused on the database industry [31] - Zhengbang Technology reports a 78.08% year-on-year increase in pig sales revenue for the first ten months [32] Group 11 - Shanghai Xiba has announced that its directors are under investigation for suspected short-term trading [33] - Changgao Electric New has won a bid for a project from the State Grid worth 246 million yuan [34] - Jianghuai Automobile reports a 5.49% increase in October sales [35] Group 12 - Xintian Green Energy reports a 20.97% year-on-year decrease in power generation for October [36] - Luokang Pharmaceutical's products have been selected in the national centralized procurement [37] - Zhongyuan Home intends to invest 16 million USD in a self-built production base in Vietnam [38] Group 13 - Changcheng Technology has terminated plans for a control change and will resume trading on November 10 [39] - Poly Development reports a significant decrease in signed sales area and amount for October [40] - Wanhua Chemical's MDI phase II facility will undergo maintenance starting November 15 [41]

证券日报网讯 11月7日晚间，永安药业发布公告称，本公司部分董事、高级管理人员洪仁贵、方锡权、 王志华、熊盛捷、李少波先生，合计持有公司股份942，000股（占公司总股本比例0.3197%，占剔除公 司回购专用账户股份后的总股本比例0.3258%）计划自本公告披露之日起十五个交易日后的三个月内以 集中竞价交易方式减持公司股份不超过235，400股（占公司总股本比例0.0799%，占剔除公司回购专用 账户股份后的总股本比例0.0814%），本次减持不会导致公司控制权发生变更。 （编辑 姚尧） ...

Core Viewpoint - On November 7, Jiangsu Cable announced a plan for share repurchase, while 14 listed companies disclosed share reduction plans by their shareholders and executives [1][2]. Group 1: Share Buyback - Jiangsu Cable's controlling shareholder intends to increase its stake in the company by investing between 100 million to 150 million yuan [2]. Group 2: Share Reduction - Huahong Technology's director plans to reduce holdings by up to 2.1 million shares [2]. - Shenzhou Information's board members and senior management plan to reduce holdings by up to 0.039% of shares [2]. - Zhongying Technology's shareholder plans to reduce holdings by up to 0.77% of shares [2]. - Yong'an Pharmaceutical's directors and executives plan to collectively reduce holdings by up to 0.08% of shares [2]. - Yingshi Sheng's actual controller plans to reduce holdings by up to 1.86% of shares [2]. - Qiming Star's shareholder plans to reduce holdings by up to 0.07% of shares [2]. - Weiteou's controlling shareholder and its concerted parties plan to reduce holdings by up to 3% of shares [2]. - Diansheng Co.'s shareholders plan to reduce holdings by up to 4% of shares [2]. - Demingli's second-largest shareholder reduced holdings by 782,200 shares on November 7 [2]. - Fuchin Technology's controlling shareholder plans to reduce holdings by up to 2% of shares [2]. - Xinlong Holdings' shareholder plans to reduce holdings by up to 3% of shares [2]. - Yonghui Supermarket's executive completed a reduction of 108,700 shares on November 7 [2]. - Fangda Carbon's share repurchase account plans to reduce holdings by up to 1.88% of shares [2]. - Changbai Mountain's shareholder plans to reduce holdings by up to 1% of shares [2].

Group 1 - Jiangsu Cable's controlling shareholder plans to increase holdings by 100 million to 150 million yuan [1] - New Tian Green Energy's controlling shareholder and its concerted parties increased their shareholding ratio to 52.43% [1] - Kangyuan Pharmaceutical's six executives plan to buy no less than 120,000 shares [1] Group 2 - Electric Sound's shareholders plan to collectively reduce their holdings by no more than 4% of the company's shares [1] - Xinlong Holdings' shareholder Hainan Zhuhua plans to reduce holdings by no more than 3% [1] - Fuzhijun Technology's controlling shareholder, the Institute of Fujian Academy of Sciences, plans to reduce holdings by no more than 2% [1] Group 3 - Weiteou's controlling shareholder Liao Gaobing and Lileyuan plan to reduce holdings by 2% and 1% respectively [1] - Yingshisheng's controlling shareholder Tang Qiu plans to reduce holdings by no more than 1.86% [1] - Changbai Mountain's shareholder Jilin Sen Gong plans to reduce holdings by no more than 1% [1] Group 4 - Qiming Star's shareholder Tibet Tianchen plans to reduce holdings by no more than 0.07% [1] - Yong'an Pharmaceutical's multiple directors plan to collectively reduce holdings by no more than 235,400 shares [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced that several directors and senior management personnel plan to reduce their shareholdings in the company through centralized bidding transactions within three months after a 15 trading day period following the announcement [1] Summary by Relevant Sections - **Shareholding Details** - A total of 942,000 shares are held by the directors and senior management, accounting for 0.3197% of the total share capital and 0.3258% when excluding shares in the repurchase special account [1] - **Planned Reduction** - The planned reduction involves a maximum of 235,400 shares, which represents 0.0799% of the total share capital and 0.0814% when excluding shares in the repurchase special account [1] - **Control Implications** - The share reduction will not lead to any change in the control of the company [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-64 潜江永安药业股份有限公司 关于公司部分董事、高级管理人员 减持股份的预披露公告 公司部分董事、高级管理人员洪仁贵、方锡权、王志华、熊盛捷、李少波先 生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 潜江永安药业股份有限公司（以下简称"公司"、"本公司"）部分董事、 高级管理人员洪仁贵、方锡权、王志华、熊盛捷、李少波先生，合计持有公司股 份 942,000 股（占公司总股本比例 0.3197%，占剔除公司回购专用账户股份后的 总股本比例 0.3258%）计划自本公告披露之日起十五个交易日后的三个月内以集 中竞价交易方式减持公司股份不超过 235,400 股（占公司总股本比例 0.0799%， 占剔除公司回购专用账户股份后的总股本比例 0.0814%），本次减持不会导致公 司控制权发生变更。 公司于近日收到上述董事、高级管理人员出具的《股份减持计划告知函》， 现将具体情况公告如下： | | | | | 占公司总 | 占剔除公司回购 ...